source
- FDA imposes partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000FDA announced a partial clinical hold on Biohaven's ion channel program, affecting the epilepsy trial of the experimental drug BHV-7000. The hold was issued after the agency requested additional p…
- FDA expands approval for Bayer's lung cancer therapyThe U.S. Food and Drug Administration announced an expansion of the approved use of Bayer's lung cancer drug. The decision broadens the patient population eligible for the treatment, reflecting th…